Press release

Deutsche Biotech Innovativ AG: Further step towards a strong capital market orientation - increase of the shares available in "free float"

Hennigsdorf, 19 August 2020 - Deutsche Biotech Innovativ AG (DBI AG) (WKN: A0Z25L/ ISIN: DE000A0Z25L1). The three main shareholders of DBI AG have decided to divest a total of up to 15% of their shares in order to increase the "free float". Free float is defined as that portion of the shares of a stock corporation that is not in fixed ownership and freely traded on the stock exchange. For DBI AG, this step by the major shareholders opens up new opportunities for expanding the circle of investors in DBI AG.

Bernd Wegener, Member of the Management Board of DBI AG, commented on this:

"In principle, there is great demand for the financing of very innovative biotech companies in Germany. As a result, DBI AG's portfolio of companies in sectors of "Unmet Diagnostic and/or Medical Needs" with strong own patents and thus new benefits for patients with previously incurable or hardly curable diseases are emerging on the basis of own basic research.

To this end, DBI AG will be provided with more funds to implement its objectives.

The current investment portfolio consisting of 4TEEN4 Pharmaceuticals GmbH as well as the extremely successful companies AdrenoMed AG (sepsis research) and SphingoTec GmbH (diagnostics innovator) will be expanded by further significant investments.

In addition to the investment activities of the main shareholders, it is intended to attract further investors and shareholders to DBI AG in the future.

The three main shareholders Dres. Andreas Bergmann, Metod Miklus and Bernd Wegener currently hold directly and indirectly over 95% of DBI shares.

For new investors, however, it is necessary to increase the free float of the exchange-traded shares to over 10%, e.g. as a prerequisite for funds or institutional investors to invest in accordance with the investment guidelines.

With the intention of reinvesting the resulting proceeds predominantly in their Portfolio Companies, each of the three principal shareholders will consequently dispose of up to 5% of the share capital, i.e. a total of up to 15% of DBI AG's shares, in the coming months".

Ralf Jakobs, CFO of DBI AG since this year, added: "I am pleased and grateful for this step by our principal shareholders. This step will enable DBI AG to address new investors in a strategically sensible and targeted manner in the future in order to jointly shape the future of DBI AG".

This release expressly or implicitly contains certain forward-looking statements concerning the business activities of DBI AG or the performance of its shares. These forward-looking statements reflect the opinion of DBI AG as of the date of this release and involve certain known and unknown. risks. DBI AG's actual results or the development of its share price may differ materially from future results or developments implied by such forward-looking statements. DBI AG is under no obligation to update any forward-looking statements.